Guardant Health, Inc. (NASDAQ: GH)

Guardant Health, Inc. is a precision oncology company that provides blood and tissue tests to help guide cancer care. The company develops liquid biopsy assays that analyze tumor derived material from blood samples to support therapy selection, minimal residual disease detection and early cancer screening. Its product portfolio includes the Guardant360 CDx test for comprehensive genomic profiling, the Guardant360 Liquid test for broad biomarker analysis, the Guardant Reveal test for residual disease and recurrence monitoring, and the Shield test for colorectal cancer screening. Guardant Health also offers research focused assays such as GuardantINFINITY, GuardantOMNI, GuardantINFORM and GuardantConnect to support biopharmaceutical drug development and clinical trial matching. The Smart Platform uses proprietary chemistry, advanced algorithms and an AI enabled learning engine called InfinityAI to unlock multi modal biology from genomic epigenomic and RNA based data. The company operates clinical laboratories in the United States and partners with distributors and hospitals internationally to deliver its testing services.

Guardant Health generates revenue primarily from the sale of its diagnostic tests to healthcare providers, hospitals and health systems. The company also earns income from collaborations with biopharmaceutical companies that use its assays for companion diagnostic development, clinical trial enrollment and translational research. Additional revenue comes from licensing its Smart Platform technology and from providing data analytics services through the GuardantINFORM offering. Guardant Health receives reimbursement from commercial insurers, government programs such as Medicare and Medicaid, and from direct patient payments when applicable. International sales are supported by distributor agreements and laboratory partnerships that allow the company to offer its tests in Europe, Asia and the Middle East.

Guardant Health holds a strong position in the liquid biopsy market alongside competitors such as Foundation Medicine (Roche), Caris Life Sciences, Tempus AI, NeoGenomics, Exact Sciences, Natera, Myriad Genetics, BillionToOne, Quest Diagnostics and Laboratory Corporation of America. The company differentiates itself through its Smart Platform that combines genomic epigenomic and RNA based data to deliver high sensitivity and specificity at low cost. Its early FDA approvals for companion diagnostic use and for primary colorectal cancer screening give it regulatory advantages. Guardant Health also benefits from a broad test menu that covers therapy selection, minimal residual disease detection and multi cancer screening, and from its global partnerships with cancer centers and research institutions that facilitate adoption and reimbursement. The company reports fast turnaround times, with most results delivered within five to seven days, which supports clinical decision making and helps maintain competitive edge.

Guardant Health serves oncologists, cancer centers, primary care physicians, hospitals and health systems across the United States and internationally. Specific customers include academic medical centers such as the Vall D'Hebron Institute of Oncology in Spain, The Royal Marsden NHS Foundation Trust in the United Kingdom and Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Italy. The company also works with biopharmaceutical customers like Adicon Holdings Limited in China and collaborates with the US Department of Veterans Affairs and TRICARE to provide testing to veterans and active duty military personnel. Patients benefit from the company's tests through their treating physicians and through direct to consumer awareness efforts that support screening adherence. Guardant Health additionally works with payer organizations to secure coverage and with laboratory benefit managers to expand access to its assays.